Johnson & Johnson (JNJ) stock has risen 2.4% over the past week but slipped 3.3% in the last month, while soaring 54.0% over the past year. Wall Street’s analysts are moderately bullish, forecasting further gains with a 12‑month average price target of $264.75 versus the last closing price of $226.71.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
This implies meaningful upside potential, and the overall rating on the shares stands at Moderate Buy. For investors, this signals growing confidence that recent momentum in the business can continue, even after a strong run over the past 12 months.
Top analyst David Risinger of Leerink Partners reiterated his Buy rating on JNJ on May 15, 2026, setting a price target of $265.00. That target is close to the Street’s average and suggests room for the stock to climb further from current levels.
Risinger upgraded the shares from Market Perform to Outperform, arguing that stronger long‑term revenue and earnings growth should support a higher valuation. He expects accelerating revenue driven by new drugs, which he believes will help JNJ outperform the broader health care sector.
The core of his bullish thesis centers on several key products. Icotyde, an oral IL‑23 drug launched in April 2026 for psoriasis, is highlighted for having best‑in‑class efficacy among oral therapies, with encouraging data in inflammatory bowel disease as well.
Inlexzo, a transformational treatment for bladder cancer, recently received a reimbursement j‑code and should benefit from a favorable guideline recommendation for common non‑invasive disease. Risinger also points to Rybrevant, which is seeing faster adoption after a subcutaneous version showed better efficacy and tolerability than the older IV form.
Tremfya is another bright spot, with strong prescription growth in inflammatory bowel disease, adding to the company’s growth story. Overall, Risinger sees Johnson & Johnson positioned to deliver double‑digit revenue growth later this decade, supported by its expanding drug portfolio.
Risinger has a strong track record, ranking 92 out of 12,195 analysts, with a success rate of about 63% and an average return of 30.1% per rating. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.